M L Jaffrain-Rea
Overview
Explore the profile of M L Jaffrain-Rea including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
430
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Feola T, Pirchio R, Puliani G, Pofi R, Crocco M, Sada V, et al.
J Endocrinol Invest
. 2022 Aug;
46(1):181-188.
PMID: 36001286
Background: Sellar/parasellar lesions have been studied in the adult and paediatric age range, but during the transition age their epidemiology, clinical manifestations, management and treatment outcomes have been poorly investigated....
2.
Bona C, Prencipe N, Jaffrain-Rea M, Carosi G, Lanzi R, Ambrosio M, et al.
J Endocrinol Invest
. 2020 Jun;
44(3):531-539.
PMID: 32594452
Purpose: The aim of this study was to evaluate the somatotroph axis in a large series of patients with prolactinoma to verify the prevalence of silent acromegaly in this population....
3.
Villa C, Vasiljevic A, Jaffrain-Rea M, Ansorge O, Asioli S, Barresi V, et al.
Virchows Arch
. 2019 Oct;
475(6):687-692.
PMID: 31578606
The 2017 World Health Organization (WHO) classification proposes to type and subtype primary adenohypophyseal tumours according to their cell lineages with the aim to establish more uniform tumour groups. The...
4.
Franck S, Korevaar T, Petrossians P, Daly A, Chanson P, Jaffrain-Rea M, et al.
Eur J Endocrinol
. 2017 Jan;
176(4):421-431.
PMID: 28100630
Background: Effective treatment of acromegaly with pegvisomant (PEGV), a growth hormone receptor antagonist, requires an appropriate dose titration. PEGV doses vary widely among individual patients, and various covariates may affect...
5.
Filopanti M, Olgiati L, Mantovani G, Corbetta S, Arosio M, Gasco V, et al.
J Clin Endocrinol Metab
. 2011 Dec;
97(2):E165-72.
PMID: 22162472
Context: The influence of full-length GH receptor (GHR) and exon 3-deleted GHR (d3GHR) on responsiveness to pegvisomant (PEG-V) in acromegalic patients is uncertain. Objective: The aim of the study was...
6.
Occhi G, Jaffrain-Rea M, Trivellin G, Albiger N, Ceccato F, De Menis E, et al.
J Endocrinol Invest
. 2010 Apr;
33(11):800-5.
PMID: 20354355
Background: Mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene have been described in about 15% of kindreds with familial isolated pituitary adenomas and in a minority of early...
7.
Filopanti M, Barbieri A, Angioni A, Colao A, Gasco V, Grottoli S, et al.
Pharmacogenomics J
. 2008 Mar;
8(5):357-63.
PMID: 18332900
Dopamine-agonist cabergoline (CB) reduces prolactin (PRL) secretion and tumor size in 80% of patients with prolactin-secreting adenomas (PRL-omas) by binding type 2 dopamine receptor (DRD2). The mechanisms responsible for resistance...
8.
Fratticci A, Grieco F, Spilioti C, Giangaspero F, Ventura L, Esposito V, et al.
J Endocrinol
. 2007 Sep;
194(3):475-84.
PMID: 17761887
Basic helix-loop-helix (bHLH) transcription factors are involved in neuroendocrine cell growth and differentiation. Though NeuroD1 is viewed as corticotroph specific, its overexpression in non-corticotroph pituitary adenomas (PAs) may reflect the...
9.
Theodoropoulou M, Arzberger T, Gruebler Y, Jaffrain-Rea M, Schlegel J, Schaaf L, et al.
J Endocrinol
. 2004 Nov;
183(2):385-94.
PMID: 15531726
The oncogenic effects of epidermal growth factor (EGF) have long been established. EGF receptor (EGFr) is overexpressed in many types of tumors and constitutes a target for cancer treatment. The...
10.
Ferretti E, Di Stefano D, Zazzeroni F, Gallo R, Fratticci A, Carfagnini R, et al.
J Endocrinol Invest
. 2004 Feb;
26(10):957-65.
PMID: 14759067
Among the transcription factors involved in pituitary ontogenesis and physiology, basic helix-loop-helix (bHLH) have been poorly studied. Members of bHLH family include NeuroD1 and ASH1, both involved in neuroendocrine differentiation....